Nebivolol Mitigate the Hepatic Expression Level of Inducible and Endothelial Nitric Oxide Synthase in Tamoxifen-Induced Oxido-Inflammatory Changes in Female Rats
DOI:
https://doi.org/10.31351/vol34iss2pp98-107Keywords:
Hepatotoxicity, Tamoxifen, Nebivolol, iNOS, eNOSAbstract
Liver injury can arise post-exposure to drugs or their metabolites, herbal and dietary supplements. Tamoxifen is a famous drug used in breast cancer treatment. Long-term tamoxifen treatment has been associated with the development of hepatotoxicity. Oxidative stress, fatty changes, and inflammation are the major implicated mechanisms contributing to tamoxifen hepatotoxicity including the iNOS-mediated inflammatory pathway in addition to standard hepatotoxicity biomarkers like alanine aminotransferase (ALT) and aspartate aminotransferase (AST). Nebivolol is a third-generation selective beta1-adrenergic receptor blocker with vasodilator characteristics with significant antioxidant activity. The present study was designed to investigate the possible protective role of nebivolol against rat hepatotoxicity induced by tamoxifen. Rats utilized in this study were randomized into 5 groups (6 rats per group); Group 1- (Control) rats received distilled water (5mL/kg b.w. orally) for 14 consecutive days. Group 2- Rats received tamoxifen (75mg/kg b.w., orally) on days 13,14 only. Group 3- Rats received Nebivolol (5 mg/kg b.w., orally for 14 consecutive days) and tamoxifen (75mg/kg b.w., orally) on days 13,14 only. Group 4- Rats received Nebivolol (8 mg/kg b.w., orally for 14 consecutive days) and tamoxifen (75mg/kg b.w., orally) on days 13,14 only. Group 5- Rats received Nebivolol (8 mg/kg b.w., orally for 14 consecutive days) and tamoxifen (75mg/kg b.w., orally) on days 13,14 only. pre-administration of nebivolol at different doses with tamoxifen showed significant downregulation (P<0.05) in hepatic AST, ALT, and iNOS with overexpression of eNOS compared to corresponding levels in the tamoxifen-only treated group. In conclusion, this study demonstrated that pre-administration of nebivolol in different doses with tamoxifen resulted in attenuation of its hepatotoxicity by the utilization of selected parameters.
How to Cite
Publication Dates
Received
Revised
Accepted
Published Online First
References
Fontana RJ, Liou I, Reuben A, Suzuki A, Fiel MI, Lee W, et al. AASLD practice guidance on drug, herbal, and dietary supplement-induced liver injury. Hepatology. 2023;77(3):1036-65.
Buhrow SA, Koubek EJ, Goetz MP, Ames MM, Reid JM. Development and validation of a liquid chromatography-mass spectrometry assay for quantification of Z- and E- isomers of endoxifen and its metabolites in plasma from women with estrogen receptor-positive breast cancer. J Chromatogr B Analyt Technol Biomed Life Sci. 2023 Apr 15; 1221:123654. doi: 10.1016/j.jchromb.2023.123654.
VALLET, Amandine, et al. The AF-2 cofactor binding region is key for the selective SUMOylation of estrogen receptor alpha by antiestrogens. Journal of Biological Chemistry, 2023, 299.1.
Chan, Carmen WH, et al. "Pharmacogenomics of breast cancer: highlighting CYP2D6 and tamoxifen." Journal of Cancer Research and Clinical Oncology 146 (2020): 1395-1404.
Famurewa AC, Ekeleme-Egedigwe CA, David EE, Eleazu CO, Folawiyo AM, Obasi NA. Zinc abrogates anticancer drug tamoxifen-induced hepatotoxicity by suppressing redox imbalance, NO/iNOS/NF-ĸB signaling, and caspase-3-dependent apoptosis in female rats. Toxicol Mech Methods. 2020 Feb;30(2):115-123. doi: 10.1080/15376516.2019.1669243. Epub 2019 Oct 1. PMID: 31532279.
Iwakiri Y, Kim MY. Nitric oxide in liver diseases. Trends in Pharmacological sciences. 2015;36(8):524-36.
Du, Wei, and Lin Wang. "The crosstalk between liver sinusoidal endothelial cells and hepatic microenvironment in nash related liver fibrosis." Frontiers in Immunology 13 (2022): 936196
.Schulz M, Klopp-Schulze L, Keilhack S, Meyer S, Botermann L, Kloft C. Adherence to tamoxifen in breast cancer patients: What role does the pharmacist play in German primary care? Can Pharm J (Ott). 2018 Dec 20;152(1):28-34. doi: 10.1177/1715163518815720. PMID: 30719195; PMCID: PMC6346334.
Cominacini L, Fratta Pasini A, Garbin U, et al. Nebivolol and its 4-keto derivative increase nitric oxide in endothelial cells by reducing its oxidative inactivation. J Am Coll Cardiol. 2003;42:1838–1844.
Whaley-Connell A, Habibi J, Johnson M, et al. Nebivolol reduces proteinuria and renal NADPH oxidase-generated reactive oxygen species in the transgenic Ren2 rat. Am J Nephrol. 2009;30:354–360.
Cerna P, Kotyzova D, Eybl V. The effect of the oral iron chelator deferiprone on the liver damage induced by tamoxifen in female rats. Hemoglobin. 2011;35(3):255-61.
Mizar SM, Omar HA, El Sherbiny GA, El-moselhy MA. Nebivolol and chrysin protect the liver against ischemia/reperfusion-induced injury in rats. Beni-Suef University Journal of Basic and Applied Sciences. 2015;4(1):86-92.
Teixeira C, Franco E, Oliveira PA, Colaco B, Gama A, Carrola J, et al. Effects of nebivolol on liver fibrosis induced by bile duct ligation in Wistar rats. in vivo. 2013;27(5):635-40.
Refaie MMM, El-Hussieny M, Zenhom NM. Protective role of nebivolol in cadmium-induced hepatotoxicity via downregulation of oxidative stress, apoptosis, and inflammatory pathways. Environ Toxicol Pharmacol. 2018; 58:212-9.
Aldrich S. Aspartate Aminotransferase (AST) Activity Assay Kit. 2017;1–4.
Aldrich S. Alanine Aminotransferase Activity Assay Kit. 2017;1–4.
Elabscience. Immunohistochemistry kit protocol.Available from: [email protected]@elabscience.com, other:www.elabsc ience.comwww.elabscience.com.
Dabbs DJ. Diagnostic Immunohistochemistry E-Book. Elsevier Health Sciences; 2013. 1157 p.
SAS.2010.SAS/STAT Users Guide for Personal Computer. Release 9.13.SAS Institute, Inc., Cary, N.C., USA.
Hamdan, Sarah Saad, Yassir Mustafa Kamal, and Huda Jaber Waheed. "Astaxanthin effect on apoptotic biomarkers in methotrexate-induced liver injury." Al Mustansiriyah Journal of Pharmaceutical Sciences 22.3 (2022): 43-50.
Hamdan, S. S., Kamal, Y. M., & Waheed, H. J. (2022). Astaxanthin affects oxidative stress biomarkers in methotrexate-induced hepatotoxicity. International Journal of Health Sciences, 6(S6), 10584–10596.
Bradbury M, Hutton B, Beltran-Bless A-A, Alzahrani M, Lariviere T, Fernandes R, et al. Time to update evidence-based guideline recommendations about concurrent tamoxifen and antidepressant use? A systematic review. Clinical Breast Cancer. 2022;22(3): e362-e73.
Saeed, I. J. R., Jassim, O. A., & Mahdi, M. A. (2022). Fatty liver formation in patients with breast cancer on tamoxifen therapy in Iraqi females. International Journal of Health Sciences, 6(S1), 3539≤ 3547. https://doi.org/10.53730/ijhs.v6nS1.5369.
Abdulkareem, N.M.; Bhat, R.; Powell, R.T.; Chikermane, S.; Yande, S.; Trinh, L.; Abdelnasser, H.Y.; Tabassum, M.; Ruiz, A.; Sobieski, M.; et al. Screening of GPCR drugs for repurposing in breast cancer. Front. Pharmacol. 2022, 13, 1049640.
Sheet EG, Tabou ZA-A, Kasim WH. Histological and Histochemical Study on the Effect of Tamoxifen on Liver of Adult Female Albino Rats and Possible Ameliorating Role of Coenzyme Q10. Journal of Pharmaceutical Negative Results. 2022;13.
Zhou W-b, Zhang X-x, Cai Y, Sun W, Li H. Osthole prevents tamoxifen-induced liver injury in mice. Acta pharmacologica sinica. 2019;40(5):608-19.
Di Pasqua, L.G.; Cagna, M.; Berardo, C.; Vairetti, M.; Ferrigno, A. Detailed Molecular Mechanisms Involved in Drug-Induced Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis: An Update. Biomedicines 2022, 10, 194. https://doi.org/10.3390/biomedicines10010194.
Pekgöz S, Asci H, Erzurumlu Y, Savran M, Ilhan I, Hasseyid N, et al. Nebivolol alleviates liver damage caused by methotrexate via AKT1/Hif1α/eNOS signaling. Drug and Chemical Toxicology. 2022;45(5):2153-9.
Mohammad BI. Hepatoprotective potentials of nebivolol and aliskiren on methotrexate-induced liver toxicity. Med J Babylon. 2014; 7:16.
Karam HM, Galal SM, Lotfy DM. Nrf2 and NF‐қB interplay in tamoxifen‐induced hepatic toxicity: A promising therapeutic approach of sildenafil and low‐dose γ radiation. Environmental Toxicology. 2023.
Sumer, F., Colakoglu, M.K., Ozdemir, Y., Ozsay, O., Ilter, Ozer, Bostanci, E.B., Akoglu, M., 2017. Effect of nebivolol on liver regeneration in an experimental 70% partial hepatectomy model. Asian J. Surg. 40 375e379.
Olawi, Nasima, et al. "Nebivolol in the treatment of arterial hypertension." Basic & Clinical Pharmacology & Toxicology 125.3 (2019): 189-201
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Iraqi Journal of Pharmaceutical Sciences
This work is licensed under a Creative Commons Attribution 4.0 International License.
